Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CORY L CONNIFF

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1376539726
CMS profile
152458
Location
ORLAND PARK, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,384.86

134 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,338.86 133
Education $46.00 1

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CORY L CONNIFF

NPI 1376539726 · CMS profile ID 152458

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

ORLAND PARK, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1376539726?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CORY L CONNIFF, NPI 1376539726, CMS profile ID 152458. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1376539726?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). CORY L CONNIFF, NPI 1376539726, CMS profile ID 152458. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1376539726?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
CORY L CONNIFF, NPI 1376539726, CMS profile ID 152458, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1376539726?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

134 matching records · $2,384.86 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 134 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–134 of 134.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim Pharmaceuticals, Inc. $21.8204/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763766006 CMS
Amgen Inc. $32.6404/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825232695 CMS
UCB, Inc. $23.2504/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807335187 CMS
Horizon Therapeutics plc $18.9004/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797100629 CMS
E.R. Squibb & Sons, L.L.C. $2.5004/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783503495 CMS
E.R. Squibb & Sons, L.L.C. $17.4004/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783503497 CMS
UCB, Inc. $21.7804/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807302485 CMS
Amgen Inc. $19.8803/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825232655 CMS
AbbVie Inc. $10.6503/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794281501 CMS
E.R. Squibb & Sons, L.L.C. $16.7903/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783503501 CMS
Horizon Therapeutics plc $4.5203/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797100625 CMS
Novartis Pharmaceuticals Corporation $7.7403/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812643543 CMS
E.R. Squibb & Sons, L.L.C. $2.0003/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783503479 CMS
E.R. Squibb & Sons, L.L.C. $13.8203/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783503481 CMS
Horizon Therapeutics plc $22.3503/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797100620 CMS
Lilly USA, LLC $24.8002/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819023481 CMS
Amgen Inc. $29.3802/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825232691 CMS
Janssen Biotech, Inc. $19.5902/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788168581 CMS
UCB, Inc. $16.1702/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807299723 CMS
E.R. Squibb & Sons, L.L.C. $20.1802/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783503485 CMS
Horizon Therapeutics plc $10.5602/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797100615 CMS
Horizon Therapeutics plc $4.0702/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797100611 CMS
Lilly USA, LLC $3.3602/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819021805 CMS
Lilly USA, LLC $3.6202/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819023485 CMS
AbbVie Inc. $20.8702/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794281499 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.9601/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763766008 CMS
Amgen Inc. $8.7001/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825232687 CMS
Lilly USA, LLC $23.7301/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819036079 CMS
Horizon Therapeutics plc $21.7101/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797100607 CMS
AbbVie Inc. $14.5401/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794281497 CMS
Amgen Inc. $26.7901/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825232723 CMS
E.R. Squibb & Sons, L.L.C. $17.3301/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783503483 CMS
Amgen Inc. $23.7301/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825232719 CMS
Horizon Therapeutics plc $9.7301/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797100603 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,152.84 123
PY2020 $1,488.35 91
PY2021 $2,384.86 134
PY2022 $2,553.36 118
PY2023 $3,361.64 124
PY2024 $2,718.64 107
PY2025 $2,538.99 106

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $102,345.65 41
PY2024 Principal investigator $56,251.40 28
PY2023 Principal investigator $180,001.85 53
PY2022 Principal investigator $121,884.65 56
PY2021 Principal investigator $15,617.68 23
PY2019 Principal investigator $1,000.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

41 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ARGENX US, INC. $3,484.00 11/20/2025 Non-covered Recipient Entity
Clinical Investigation Specialists, Inc
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148064
Principal investigator 1 ARGENX US, INC. $1,916.00 11/20/2025 Non-covered Recipient Entity
Clinical Investigation Specialists, Inc
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148088
Principal investigator 1 ARGENX US, INC. $721.00 11/20/2025 Non-covered Recipient Entity
Clinical Investigation Specialists, Inc
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148102
Principal investigator 1 ARGENX US, INC. $721.00 11/20/2025 Non-covered Recipient Entity
Clinical Investigation Specialists, Inc
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148106
Principal investigator 1 ARGENX US, INC. $1,868.00 10/20/2025 Non-covered Recipient Entity
Clinical Investigation Specialists, Inc
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148070
Principal investigator 1 ARGENX US, INC. $6,483.00 10/20/2025 Non-covered Recipient Entity
Clinical Investigation Specialists, Inc
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148074
Principal investigator 1 ARGENX US, INC. $2,003.00 10/20/2025 Non-covered Recipient Entity
Clinical Investigation Specialists, Inc
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148080
Principal investigator 1 ARGENX US, INC. $4,505.00 10/20/2025 Non-covered Recipient Entity
Clinical Investigation Specialists, Inc
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148085
Principal investigator 1 Janssen Research & Development, LLC $12,500.00 10/06/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175400201
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 10/06/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175400214
Principal investigator 1 ARGENX US, INC. $7,500.00 10/02/2025 Non-covered Recipient Entity
Clinical Investigation Specialists, Inc
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148061
Principal investigator 1 ARGENX US, INC. $329.90 10/02/2025 Non-covered Recipient Entity
Clinical Investigation Specialists, Inc
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148092
Principal investigator 1 ARGENX US, INC. $2,500.00 10/02/2025 Non-covered Recipient Entity
Clinical Investigation Specialists, Inc
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148098
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 08/08/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS INC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223283971
Principal investigator 1 ARGENX US, INC. $106.00 08/04/2025 Non-covered Recipient Entity
Greater Chicago Specialty Physicians
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150531
Principal investigator 1 ARGENX US, INC. $26.50 08/04/2025 Non-covered Recipient Entity
Greater Chicago Specialty Physicians
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150535
Principal investigator 1 ARGENX US, INC. $75.20 08/04/2025 Non-covered Recipient Entity
Greater Chicago Specialty Physicians
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150538
Principal investigator 1 ARGENX US, INC. $35.80 08/04/2025 Non-covered Recipient Entity
Greater Chicago Specialty Physicians
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150542
Principal investigator 1 ARGENX US, INC. $382.00 08/04/2025 Non-covered Recipient Entity
Greater Chicago Specialty Physicians
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150547
Principal investigator 1 ARGENX US, INC. $2.80 08/04/2025 Non-covered Recipient Entity
Greater Chicago Specialty Physicians
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150551
Principal investigator 1 ARGENX US, INC. $103.50 08/04/2025 Non-covered Recipient Entity
Greater Chicago Specialty Physicians
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150555
Principal investigator 1 ARGENX US, INC. $573.00 08/04/2025 Non-covered Recipient Entity
Greater Chicago Specialty Physicians
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150558
Principal investigator 1 ARGENX US, INC. $5.95 08/04/2025 Non-covered Recipient Entity
Greater Chicago Specialty Physicians
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150562
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,370.00 08/01/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS INC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223283515
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,500.00 08/01/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS INC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223283517
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $937.00 08/01/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS INC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223283519
Principal investigator 1 ARGENX US, INC. $159.00 06/18/2025 Non-covered Recipient Entity
Greater Chicago Specialty Physicians
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150504
Principal investigator 1 ARGENX US, INC. $75.20 06/18/2025 Non-covered Recipient Entity
Greater Chicago Specialty Physicians
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150508
Principal investigator 1 ARGENX US, INC. $71.60 06/18/2025 Non-covered Recipient Entity
Greater Chicago Specialty Physicians
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150511
Principal investigator 1 ARGENX US, INC. $764.00 06/18/2025 Non-covered Recipient Entity
Greater Chicago Specialty Physicians
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150515
Principal investigator 1 ARGENX US, INC. $106.75 06/18/2025 Non-covered Recipient Entity
Greater Chicago Specialty Physicians
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150519
Principal investigator 1 ARGENX US, INC. $51.75 06/18/2025 Non-covered Recipient Entity
Greater Chicago Specialty Physicians
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150522
Principal investigator 1 ARGENX US, INC. $11.20 06/18/2025 Non-covered Recipient Entity
Greater Chicago Specialty Physicians
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237150526
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,983.15 06/11/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS INC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246431030
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $300.16 04/07/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS INC
INSPIRE LTE study No dispute reported 06/30/2026 1246431036
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,747.98 03/14/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS INC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246431024
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $145.35 03/12/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS INC
INSPIRE LTE study No dispute reported 06/30/2026 1246431034
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $967.14 03/03/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS INC
INSPIRE LTE study No dispute reported 06/30/2026 1246431026
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $11,263.19 01/21/2025 Non-covered Recipient Entity
Greater Chicago Specialty Physicians
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) No dispute reported 06/30/2026 1235997047
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $16,336.31 01/21/2025 Non-covered Recipient Entity
Greater Chicago Specialty Physicians
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease-modifying Anti-rheumatic Drugs No dispute reported 06/30/2026 1235997049
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,714.22 01/21/2025 Non-covered Recipient Entity
Greater Chicago Specialty Physicians
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (POETYK SLE-2) No dispute reported 06/30/2026 1235997051